Evaluation of Nirsevimab and hRSV Severity Risk Factors on hRSV Admissions
Document Type
Conference Proceeding - Restricted Access
Publication Date
5-9-2025
Abstract
Human Respiratory Syncytial Virus (hRSV) is a common respiratory pathogen, primarily affecting infants and young children. In the United States, hRSV is a leading cause of hospitalization in this age group. Currently, there is no treatment for acute hRSV. Palivizumab was the first monoclonal antibody (mAB) approved for hRSV prevention in 1998. In 2023, nirsevimab, was approved for hRSV prevention and was preferred due to the long-half life. High demand led to a shortage during its first season, prompting American Academy of Pediatrics (AAP)/Advisory Committee for Immunization Practices (ACIP) recommendations to restrict use of mAB therapy to high-risk infants. Corewell Health implemented restrictions on nirsevimab administration for high-risk patients in October 2023. This study aims to evaluate the impact of these restrictions on hRSV admissions, guiding institutional nirsevimab use.
Recommended Citation
Grofvert J, Ogrin S, Leffler L. Evaluation of nirsevimab and hRSV severity risk factors on hRSV admissions. Presented at: Research Day Corewell Health West; 2025 May 9; Grand Rapids, MI.
Comments
2025 Research Day Corewell Health West, Grand Rapids, MI, May 9, 2025. Abstract 1756